Physician

Raghav Govindarajan, MD

According to 2025 Medicare claims, Raghav Govindarajan, MD (NPI: 1639481914) practices neurology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Clair, IL. This provider's primary affiliated billing organization is HSHS MEDICAL GROUP INC (NPI: 1962644807; TIN: 263956318) and primary practice location at 62269-1282. Govindarajan is affiliated with the IRCCO (ACO ID: A2619), HSHS ACO, L.L.C. (ACO ID: A2783), and SSM IL ACO, LLC (ACO ID: A4832), participating under the MSSP model.

Govindarajan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 769 traditional Medicare patients, billed 40,102 HCPCS/CPT codes, and received $419,053 in Medicare payments. The top billing code was 95913 (Nerve conduction, 13 or more studies). Part D data shows 2,771 prescription claims across 422 beneficiaries totaling $3,895,041 in drug costs, led by Vyvgart (Efgartigimod Alfa-Fcab). DME data shows 68 claims. Open Payments data shows 235 records totaling $404,071. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $41,746 to $419,053. Similarly, Part D prescription costs have risen steadily, from $115,831 to $3,895,041. For DME billing, reported payments rose steadily, from $86,429 to $128,323.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	295	687	$41,746
2016	371	868	$54,409
2017	366	999	$54,541
2018	352	1,020	$54,722
2019	400	1,268	$69,177
2020	313	868	$41,244
2021	321	5,013	$94,305
2022	545	27,298	$290,754
2023	747	37,729	$390,702
2024	769	40,102	$419,053

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	87	450	$115,831
2016	183	1,614	$460,480
2017	203	2,310	$849,837
2018	217	2,702	$1,834,737
2019	239	3,093	$3,871,796
2020	220	3,022	$5,581,778
2021	235	1,911	$3,521,442
2022	274	1,255	$805,856
2023	321	1,618	$1,852,323
2024	422	2,771	$3,895,041

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	144	$14,758
2016	N/R	124	$69,418
2017	N/R	345	$353,598
2018	N/R	255	$383,144
2019	13	218	$389,602
2020	17	260	$207,799
2021	21	308	$212,227
2022	N/R	134	$108,387
2023	N/R	128	$112,422
2024	N/R	68	$63,713

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
95913	Nerve conduction, 13 or more studies	167	168	$211
95910	Nerve conduction, 7-8 studies	95	96	$129
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	151	197	$100
95886	Needle measurement of electrical activity in arm or leg muscles, complete study	258	334	$74
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	337	518	$66

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyvgart	Efgartigimod Alfa-Fcab	15	652	$1,006,692
Vyvgart Hytrulo	Efgartigimod-Hyaluronidas-Qvfc	12	336	$732,129
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	24	672	$354,472
Privigen	Immun Glob G(Igg)/Pro/Iga 0-50	31	816	$288,991
Ubrelvy	Ubrogepant	113	2,806	$173,121

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	68	$63,713

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	197	$149,709	ARGENX US, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	38	$254,362	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Raghav Govindarajan, MD?

Tedicare shows public-source Medicare data for Raghav Govindarajan, MD (NPI 1639481914), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Raghav Govindarajan, MD have ACO affiliation data?

Raghav Govindarajan, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), HSHS ACO, L.L.C. (MSSP, ACO ID A2783), and SSM IL ACO, LLC (MSSP, ACO ID A4832).

What billing organization is linked to Raghav Govindarajan, MD?

Raghav Govindarajan, MD is linked to HSHS MEDICAL GROUP INC (billing NPI 1962644807) in the available physician profile data.

Does Raghav Govindarajan, MD have Open Payments data?

Raghav Govindarajan, MD has 235 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.